Status:
COMPLETED
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
20+ years
Brief Summary
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting. There will be no experimental component associated with this study ...
Eligibility Criteria
Inclusion
- Documented clinical diagnosis of schizophrenia meeting the Diagnostic and Statistical Manual of Mental Disorders,(DSM-IV-TR) criteria
- Patients who already take one atypical at inclusion it is started at least 1 week and up to 4 weeks before the inclusion
Exclusion
- Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I
- Patients with antipsychotic combinations (more than two agents)
- Patients who are already on any mood stabilizers and antidepressant
- Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment
- Patients who have been treated with antipsychotics in depot formulations for the last two months
- Previous enrollment or randomisation of treatment in the present NIS
- Patients who had participated in other clinical trials within 4 weeks prior to enrollment period
- Pregnant women or women who are breast-feeding
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT01160679
Start Date
August 1 2010
End Date
August 1 2011
Last Update
August 18 2011
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Busan, Busan, South Korea
2
Research Site
Gongju, Chungcheongnam-do, South Korea
3
Research Site
Daegu, Daegu, South Korea
4
Research Site
Daejeon, Daejeon, South Korea